Display options
Cite
Keppens C, Schuuring E, Dequeker EM. Managing Deviating EQA Results: A Survey to Assess the Corrective and Preventive Actions of Medical Laboratories Testing for Oncological Biomarkers. Diagnostics (Basel). 2020;10(10)doi: 10.3390/diagnostics10100837.
Keppens, C., Schuuring, E., & Dequeker, E. M. (2020). Managing Deviating EQA Results: A Survey to Assess the Corrective and Preventive Actions of Medical Laboratories Testing for Oncological Biomarkers. Diagnostics (Basel, Switzerland), 10(10), . https://doi.org/10.3390/diagnostics10100837
Keppens, Cleo, et al. "Managing Deviating EQA Results: A Survey to Assess the Corrective and Preventive Actions of Medical Laboratories Testing for Oncological Biomarkers." Diagnostics (Basel, Switzerland) vol. 10,10 (2020). doi: https://doi.org/10.3390/diagnostics10100837
Keppens C, Schuuring E, Dequeker EM. Managing Deviating EQA Results: A Survey to Assess the Corrective and Preventive Actions of Medical Laboratories Testing for Oncological Biomarkers. Diagnostics (Basel). 2020 Oct 18;10(10). doi: 10.3390/diagnostics10100837. PMID: 33080995; PMCID: PMC7603102.
Copy Download .nbib Format: NLM
Share it on

Diagnostics (Basel). 2020 Oct 18;10(10). doi: 10.3390/diagnostics10100837.

Managing Deviating EQA Results: A Survey to Assess the Corrective and Preventive Actions of Medical Laboratories Testing for Oncological Biomarkers.

Diagnostics (Basel, Switzerland)

Cleo Keppens, Ed Schuuring, Elisabeth Mc Dequeker

Affiliations

  1. Department of Public Health and Primary Care, Biomedical Quality Assurance Research Unit, University of Leuven, Kapucijnenvoer 35d, 3000 Leuven, Belgium.
  2. Department of Pathology, University Medical Center Groningen (UMCG), University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands.

PMID: 33080995 PMCID: PMC7603102 DOI: 10.3390/diagnostics10100837

Abstract

Laboratories testing predictive biomarkers in lung and colorectal cancer are advised to participate in external quality assessment (EQA) schemes. This study aimed to investigate which corrective actions were taken by laboratories if predetermined performance criteria were not met, to ultimately improve current test practices. EQA participants from the European Society of Pathology between 2014 and 2018 for lung and colorectal cancer were contacted, if they had at least one analysis error or test failure in the provided cases, to complete a survey. For 72.4% of 514 deviating EQA results, an appropriate action was performed, most often including staff training (15.2%) and protocol revisions (14.6%). Main assigned persons were the molecular biologist (40.0%) and pathologist (46.5%). A change in test method or the use of complex techniques, such as next-generation sequencing, required more training and the involvement of dedicated personnel to reduce future test failures. The majority of participants adhered to ISO 15189 and implemented suitable actions by designated staff, not limited to accredited laboratories. However, for 27.6% of cases (by 20 laboratories) no corrective action was taken, especially for pre-analytic problems and complex techniques. The surveys were feasible to request information on results follow-up and further recommendations were provided.

Keywords: ISO 15189; colorectal cancer; corrective action; external quality assessment; laboratory accreditation; non-small cell lung cancer; preventive action; quality management

References

  1. Front Oncol. 2020 Jan 22;9:1521 - PubMed
  2. J Clin Pathol. 2014 Nov;67(11):923-31 - PubMed
  3. Virchows Arch. 2020 Oct 13;: - PubMed
  4. Health Care Financ Rev. 1989 Summer;10(4):141-6 - PubMed
  5. Arch Pathol Lab Med. 2013 Jun;137(6):828-60 - PubMed
  6. Virchows Arch. 2019 Jul;475(1):25-37 - PubMed
  7. Arch Pathol Lab Med. 2012 Feb;136(2):140-7 - PubMed
  8. Oncotarget. 2018 Apr 17;9(29):20524-20538 - PubMed
  9. J Pathol. 2014 Sep;234(1):5-10 - PubMed
  10. Cancer Treat Rev. 2016 Jan;42:56-72 - PubMed
  11. J Mol Diagn. 2018 Jul;20(4):455-464 - PubMed
  12. Virchows Arch. 2017 Jan;470(1):5-20 - PubMed
  13. Lung Cancer. 2014 Mar;83(3):309-15 - PubMed
  14. J Mol Diagn. 2018 Nov;20(6):743-753 - PubMed
  15. Biochem Med (Zagreb). 2017 Feb 15;27(1):49-62 - PubMed
  16. Clin Chem Lab Med. 2018 Sep 25;56(10):1644-1654 - PubMed
  17. Virchows Arch. 2013 Jan;462(1):27-37 - PubMed
  18. ESMO Open. 2017 May 26;2(2):e000160 - PubMed
  19. Br J Cancer. 2018 Aug;119(5):605-614 - PubMed
  20. Br J Cancer. 2014 Jul 15;111(2):413-20 - PubMed
  21. Oncologist. 2015 Mar;20(3):257-62 - PubMed
  22. Virchows Arch. 2017 Dec;471(6):721-729 - PubMed
  23. J Mol Diagn. 2016 Mar;18(2):205-14 - PubMed
  24. J Mol Diagn. 2018 Mar;20(2):129-159 - PubMed

Publication Types

Grant support